AstraZeneca Crestor Vs. Lipitor Study Shows Advantage In LDL, HDL Effect
This article was originally published in Pharmaceutical Approvals Monthly
Phase III results from a trial comparing AstraZeneca’s investigational HMG-CoA reductase inhibitor Crestor to Pfizer’s Lipitor demonstrated statistically significant superiority for Crestor in reducing levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apo B), as well as in raising levels of high-density lipoprotein cholesterol (HDL-C), according to an abstract.
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class